Achondroplasia Research Conference

Blog

Achondroplasia

Growing Strong

Bay Area parents Munira and Amer Haider talk about the fund they established to help support research on Achondroplasia,... Read More
Achondroplasia
BioMarin

Novel therapy improves height for children with achondroplasia

via Healio/Endocrine Today Children with a common form of skeletal dysplasia saw persistent and sustained improvements in annualized growth... Read More
Achondroplasia

Achondroplasia Growth Charts

For growth monitoring of patients with achondroplasia by Lo Neumeyer, Andrea Merker, Lars Hagenäs Clinical surveillance of infants and children... Read More
BioMarin

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in... Read More
Achondroplasia

touchEXPERT OPINIONS Clinical management strategies in achondroplasia: Current landscape and new horizons

via touchEndocrinology. Watch three leading experts explore how the pathophysiology of achondroplasia is being targeted by new and emerging... Read More
Achondroplasia

Lower limb biomechanics during gait in children with Achondroplasia

via Journal of Biomechanics.Damien Kiernan – dkiernan@crc.ie Movement Analysis Laboratory, Central Remedial Clinic, Clontarf, Dublin 3, Ireland AbstractAchondroplasia is... Read More
Achondroplasia
Ascendis
BioMarin
Pfizer
QED

Prospects for Pharmaceutical Treatment of Achondroplasia

John B. Cannon, Ph.D Achondroplasia is a form of dwarfism that occurs about once in every 20,000 births. It... Read More
BioMarin
Hypochondroplasia
Skeletal Dysplasia

Study may change treatment of childhood growth disorders

A child’s growth is often measured by pediatricians during routine physicals to identify abnormalities of growth and stature. An... Read More
QED

BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia Data Accepted to ENDO 2020

SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in... Read More
Achondroplasia
BioMarin

BioMarin – Update for Achondroplasia Associations

As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the... Read More